FAScinate Therapeutics

FAScinate Therapeutics Inc., a subsidiary of the South Korean biotechnology company Kainos Medicine Inc., is a clinical-stage biotechnology research company developing disease-modifying therapies for neurodegenerative disorders such as Parkinson's disease (PD) and multiple system atrophy (MSA). FAScinate has obtained the clinical development and commercialization rights for KM-819 from Kainos Medicine and is advancing it into Phase II studies in the United States for the treatment of Parkinson’s disease.